MELK and neoplasm: Having demonstrated that silencing of MELK and treatment with OTS167 greatly reduced prostate cancer cell proliferation and viability in vitro, we aimed to evaluate whether targeting this kinase might be a promising strategy to reduce tumour growth in vivo.